Abstract
Comparative study was performed between the two groups :39 patients treated with L-dopy and carbidopa, and 20 patients treated with L-dopa and benserazide for several years. The therapeutic efficacy and the maximal side effects were comparatively investi-gated between the two groups. The ratio of L-dopa to carbidopa was 10 and that of L-dopa to benserazide was 4. The mean grade of disability (Parkinson Score and Yahr's stage) and the mean therapeutic period did not show any significant differences between the two groups before the therapy.
The following results were obtained.
1) The maximal improvement in Parkinson Score showed no significant differences between the two groups. But the maximal improvement of Yahr's stage in the therapy of L-dopa with benseragide was significantly superior to the therapy of L-dopa with car-bidopa (p<0.05). But the improvement of Parkinson Score and Yahr's stage showed no significant differences between the two groups at the final examination. No significant difference was recognized in mean daily L-dopa dosage at the maximal therapeutic effect and final examination.
2) L-dopa-induced dyskinesis was significantly lower in the group of L-dopa and ben-serazide than the group of L-dopa and carbidopa (p<0.05). The frequency of gastric and autonomic side effects in the group of L-dopa and carbidopa was higher than the group of L-dopa and benserazide without any statistical significance. As to the psychiatric side effects severe symptoms were seen only in the group of L-dopa and carbidopa. The mean daily L-dopa dosage showed no significant differences between the two groups with refe-rence to the side effects.
3) From the standpoint mentioned above, it was concluded that the therapy of L-dopa with benserazide (the ratio of L-dopa to benserazide was 4) was significantly superior to the therapy of L-dopa with carbidopa (the ratio of L-dopa to carbidopa was 10). The neuropharmacological analysis between carbidopa and benserazide was also discussed
